CancerPlexSM is a comprehensive genetic assessment of a patient’s tumor that guides oncologists towards effective treatment options. What is CancerPlex? CancerPlex is a next generation DNA sequencing test for solid SM tumors. The specific coding regions of over 400 known cancer Potential outcomes from CancerPlex genes are simultaneously determined using a small amount of Identification of variants associated with response or resis- DNA extracted from tumor samples, including formalin-fixed, tance to an FDA-approved therapy for the patient’s disease. paraffin-embedded (FFPE) tissue and cell blocks from fine-needle aspirates or effusions. This analysis is performed in a single assay, Identification of variants associated with response or resis- simplifying and streamlining the test ordering process, and eliminat- tance to a therapy associated with another clinical indication. ing time consuming serial testing. Clinically actionable information unique to each patient’s tumor is consolidated into a simple report. Identification of variants associated with a therapy(s) in CancerPlex reveals missense changes, insertions and deletions, clinical development. and previously described rearrangements of ALK, RET, and ROS. Benefits of CancerPlex: CancerPlex genes were selected because of their importance in tumor The average turn-around-time for CancerPlex is under 10 biology. Analyzing more genes increases the chance of discovering business days, dramatically shortening the waiting period for actionable findings that lead to more choices for treatment. Our initial the start of treatment. results indicate that CancerPlex analysis identifies actionable findings up to 20% more frequently than previously published studies. CancerPlex ordering is simple: KEW provides all necessary shipping materials, can facilitate tissue retrieval and return with Since knowledge of tumor biology changes rapidly, CancerPlex pathologists, and manages 3rd party payment for the test. incorporates genes that are actionable today using both approved therapies and therapies in clinical development. Hot-spot analysis may miss up to 20% of clinically important mutations in some tumors. CancerPlex sequences the coding regions Contact KEW of genes, detecting novel or rare alterations that are missed by other 840 Memorial Drive testing modalities. Cambridge, MA 02139 CancerPlex reports are easy for oncologists to interpret and translate www.kewgroup.com into care decisions. KEW’s Therapeutic Pathways provide valuable For inquiries: +(1) 617-945-7922 information about the most current updates in cancer care. or [email protected] This gene list is representative of the genes analyzed in CancerPlex and was created from extensive analysis of scientific literature. For detailed information on the region of interest, please contact a CancerPlex specialist at [email protected]. The highlighted genes are both sequenced and analyzed for previously described gene rearrangements. GENE LIST ABL1 BTK DDIT3 FGF23 IDH2 MAP2K2 NOTCH1 PRKDC STAG2 ABL2 BUB1B DDR1 FGF3 IGF1R MAP2K4 NOTCH2 PSIP1 STAT3 ACVR1B C11orf30 DDR2 FGF4 IGF2 MAP3K1 NOTCH4 PTCH1 STAT4 ACVR2A CARD11 DICER1 FGF6 IGF2R MAP3K7 NPM1 PTEN STK11 AFF1 CASP8 DNMT3A FGFR1 IKBKB MAPK1 NRAS PTGS2 STK36 AKT1 CBFB DOT1L FGFR2 IKBKE MAPK8 NTRK1 PTPRD SUFU AKT2 CBL DST FGFR3 IKZF1 MBD1 NTRK2 PTPRT SYK AKT3 CCND1 EDNRB FGFR4 IL2 MCL1 NTRK3 RAC1 TAF1 ALK CCND2 EGFR FH IL21R MDM2 NUMA1 RAF1 TAF1L AMER1 CCND3 EML4 FLCN IL6ST MDM4 NUP214 RALGDS TAL1 APC CCNE1 EP300 FLI1 IL7R MED12 NUP93 RARA TBX22 AR CD70 EPHA3 FLT1 INHBA MEF2B NUP98 RASA1 TCF12 ARAF CD79A EPHA5 FLT3 IRF4 MEN1 PAK3 RB1 TCF3 ARFRP1 CD79B EPHA7 FLT4 IRS2 MET PALB2 REL TCF7L1 ARID1A CDC73 EPHB1 FN1 ITGA10 MITF PARP1 RET TCF7L2 ARID2 CDH1 EPHB4 FOXA1 ITGB2 MLH1 PAX3 RHOH TCL1A ARNT CDH11 EPHB6 FOXL2 ITGB3 MMP2 PAX5 RICTOR TET1 ASCL4 CDH2 ERBB2 FOXO1 JAK1 MN1 PAX7 RNASEL TET2 ASXL1 CDH5 ERBB3 FOXP1 JAK2 MPL PAX8 RNF2 TFE3 ATM CDK12 ERBB4 G6PD JAK3 MRE11A PBRM1 RNF43 TGFBR2 ATR CDK4 ERCC1 GATA1 JUN MSH2 PBX1 ROS1 TGM7 ATRX CDK6 ERCC2 GATA2 KAT6A MSH6 PDGFRA RPS6KA2 TLR4 AURKA CDK8 ERCC3 GATA3 KAT6B MST1R PDGFRB RPTOR TNFAIP3 AURKB CDKN1A ERCC4 GDNF KDM5A MTOR PDK1 RRM1 TNFRSF14 AURKC CDKN1B ERCC5 GID4 KDM5C MTR PGAP3 RUNX1 TNK2 AXIN2 CDKN2A ERG GNA11 KDM6A MTRR PHOX2B RUNX1T1 TOP1 AXL CDKN2B ESR1 GNA13 KDR MUTYH PIK3C2B SAMD9 TP53 BAP1 CDKN2C ETS1 GNAQ KEAP1 MYC PIK3CA SDHB TP63 BARD1 CEBPA ETV1 GNAS KIAA1804 MYCL PIK3CB SETD2 TPR BCL10 CHEK1 ETV4 GPC6 KIT MYCN PIK3CD SF3B1 TRIM33 BCL11A CIC EXT1 GPR124 KLF5 MYD88 PIK3CG SGK1 TRIP11 BCL11B CREBBP EXT2 GRIK3 KLF6 MYH11 PIK3R1 SH2D1A TRRAP BCL2 CRKL EZH2 GRIN2A KLHL6 MYH9 PIK3R2 SLIT2 TSC1 BCL2L1 CRLF2 FAM46C GSK3B KMT2A NBN PIK3R3 SMAD2 TSC2 BCL2L2 CRTC1 FANCA HCAR1 KMT2D NCOA1 PIM1 SMAD4 TSHR BCL6 CSF1R FANCC HCN1 KRAS NCOA2 PKHD1 SMARCA4 TYK2 BCL9 CSMD3 FANCE HGF LAMP1 NCOA4 PLAG1 SMARCB1 UBR5 BCOR CTCF FANCF HIF1A LCK NF1 PLCG1 SMO USP9X BCORL1 CTNNA1 FANCG HLF LPP NF2 PML SOCS1 VHL BIRC2 CTNNA2 FANCL HNF1A LRP1B NFE2L2 PMS1 SOX10 WISP3 BIRC3 CTNNB1 FAS HNF4A LTF NFKB1 POT1 SOX11 WT1 BLM CUX1 FAT1 HRAS MAGEA1 NFKB2 PPARG SOX2 XPC BLNK CYLD FBXW7 HSP90AA1 MAGI1 NFKBIA PPP2R1A SOX9 XPO1 BMPR1A DAXX FGF10 HSP90AB1 MALT1 NIN PPP6C SPEN ZNF384 BRAF DCC FGF14 ICK MAML2 NKX2-1 PRDM1 SPOP ZNF521 BRIP1 DDB2 FGF19 IDH1 MAP2K1 NLRP1 PRKAR1A SRC.